ANTIVIRAL RESEARCH, cilt.150, ss.9-14, 2018 (SCI İndekslerine Giren Dergi)
Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries.